Pharmaceuticals
Healthcare
True North-backed Integrace set to add new names on cap table
Mumbai-based pharmaceutical player Integrace Pvt. Ltd, backed by Singapore’s Temasek and homegrown private equity firm......
Healthcare
Piramal-Bain's India Resurgence Fund in talks for stake in pharma player
India Resurgence Fund (IndiaRF), a stressed assets investment platform co-floated by Piramal Group and Bain Capital, is ......
Healthcare
Searchlight: Pulse Pharma's revenue is slowing again. Can it pick up pace?
Hyderabad-based therapeutic medicines manufacturer, Pulse Pharmaceuticals Pvt. Ltd recorded weak revenue growth for the ......
Healthcare
Quadria Capital mulls another exit from India portfolio
Healthcare-focused private equity firm Quadria Capital is planning to offload its stake in a three-year old portfolio ......
Healthcare
Suven Pharma mulls inorganic push for its core business
Private equity giant Advent-owned Suven Pharmaceuticals Ltd is scouting for acquisitions in the technology space to ......
Healthcare
Iron Pillar, Kalaari & Navam-backed Vyome set for NASDAQ debut with reverse merger
Vyome Therapeutics Inc, a clinical-stage healthcare company targeting immunoinflammatory and rare diseases in the US and other global markets,......
Healthcare
Morocco's Laprophan Group set to acquire local natural food supplement brand
Moroccan pharmaceuticals major The Laprophan Group is set to acquire a majority stake in a natural food supplement ......
Healthcare
Searchlight: MSN Labs gunning for growth in FY25 with diversification plans
MSN Laboratories Pvt. Ltd, a Hyderabad-based pharma player focused on active pharmaceutical ingredients (APIs) and ......
Healthcare
Can Bioplus bounce back from revenue stagnation after PE investor's exit?
Healthcare supplements maker Bioplus Life Sciences Pvt. Ltd, which was a portfolio company for Asia-focused private ......
Healthcare
Searchlight: Emnar Pharma poised to turn around after a decline in FY23 financials
Emnar Pharma Pvt. Ltd (formerly Emmennar Pharma), a part of the Virchow group, is likely to see a rebound in ......